Growth Hormone & Performance

GHRP-6

An older appetite-forward GH secretagogue signal.

Last updated 12 August 2026

Studied forHunger and weight gain · GH pulse · Class comparison

Evidence on file3 animal studies · 3 citations not yet graded

Strongest sourceGhrelin impairs embryo development after ovarian hyperstimulation. (animal study)

Mechanism

GHS-R1a agonist with stronger hunger, cortisol, and prolactin effects than newer agents.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

Hunger and weight gain
GH pulse
Class comparison

Dosing on file unverified

100-300 mcg daily, cycled 8–12 weeks

Reported dose	Volume	Draw
Low — 100 mcg	0.1 mL	10 units
High — 300 mcg	0.3 mL	30 units

What that assumes. Assumes 2 mg in 2 mL (1000 mcg/mL) drawn on a U-100 barrel — the preset on this record, not a recommendation and not the only way to mix it. Change the vial mass, the diluent or the barrel and every number in this table changes. Run your own.

Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.

Reconstitution

Vial	Diluent	Concentration	Typical dose	Draw
2 mg	2 mL	1000 mcg/mL	100 mcg	10 units

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Reported adverse effects

Marked increase in appetite

Very commononset: Post-injectionreported reversible
Water retention

Commononset: First weeksreported reversible

Literature on file 6

animal in vivo
Ghrelin impairs embryo development after ovarian hyperstimulation. graded on: an animal model — read from the indexed abstract — “Mice”
animal in vivo
Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation. graded on: an animal model — read from the indexed abstract — “rats”
animal in vivo
Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis. graded on: an animal model — read from the indexed abstract — “Mice”

Not graded

3 citations whose study design could not be read from the title. Left ungraded rather than guessed at.

Identity

Space-filling 3D model of GHRP-6, carbon grey, nitrogen blue, oxygen red — Built from the SMILES on this record — the atoms, bonds and stereochemistry are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

2D chemical structure of GHRP-6 — Built from the SMILES on this record — the atoms, bonds and stereochemistry are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

Molecular weight: 873.0
Molecular formula: C46H56N12O6
PubChem CID: 4345065
InChI key: WZHKXNSOCOQYQX-UHFFFAOYSA-N
Sequence: HWAWFK
SMILES: CC(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC4=CNC5=CC=CC=C54)NC(=O)C(CC6=CN=CN6)N
InChI: InChI=1S/C46H56N12O6/c1-27(54-44(62)39(20-29-23-51-35-15-7-5-13-32(29)35)57-43(61)34(48)22-31-25-50-26-53-31)42(60)56-40(21-30-24-52-36-16-8-6-14-33(30)36)46(64)58-38(19-28-11-3-2-4-12-28)45(63)55-37(41(49)59)17-9-10-18-47/h2-8,11-16,23-27,34,37-40,51-52H,9-10,17-22,47-48H2,1H3,(H2,49,59)(H,50,53)(H,54,62)(H,55,63)(H,56,60)(H,57,61)(H,58,64)

Classified as

Ghrelin Receptor Agonismmechanism: This is the mechanism behind the compounds usually filed as secretagogues, and it explains why appetite effects appear in the same records as growth hormone effects rather than as an unrelated aside.
Subcutaneousroute: This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.
Intravenousroute: A large share of the pharmacokinetic numbers attached to peptide records, half-life in particular, come from intravenous studies and often from animals. Those numbers describe an intravenous curve and do not transfer unchanged to a depot under the skin.

Also called

GHRP-6
growth hormone releasing peptide-6

Notes unverified prose

Phase 3 COURAGE-2 stroke trial: 5 mg IV BID; PK study: 100-400 mcg/kg IV; 22 human studies; Phase 3 COURAGE-2 stroke trial; 1989 human IV studies

Not on file 1

1 of the 8 fields we track hold nothing on this record, and each says why. A blank field is a bug; a named absence is a finding.

CAS registry numberthe reference database returned nothing for it

Each field links to every other record missing the same thing. The full ledger holds 521 gaps across 136 records.

Listed prices 1

What 1 shop we track listed for GHRP-6, read from their own public catalogues on 2026-08-12. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Listed in CAD
Vendor	Size	Price	Per mg
Particle Peptides Canada	5 mg	$24.60 CAD	$4.92/mg

Prices are the vendor's own listing, reproduced with the date we read it — never converted between currencies, and compared per milligram only where the vendor states the vial size.

At a glance

Strongest rung: animal in vivo
Citations: 6
Regulatory: Human research reported (unverified)
Route: Intravenous / Subcutaneous
Declared gaps: 1

Citations by rung

animal in vivo3

Strongest wins, never an average.